Transdermal nicotine for Tourette's syndrome

Drug Development Research

Volumn 38, Issue 3-4, 1996, Pages 290-298

  Shytle, R Doug ^a   Silver, Archie A ^a   Philipp, Mary Katherine ^a   McConville, Brian J ^b   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Nicotine; Tics; Tourette syndrome

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; NICOTINE; NICOTINE GUM;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL DISEASE; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SCHOOL CHILD; TASTE AVERSION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030459485     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199607/08)38:3/4<290::AID-DDR18>3.0.CO;2-2     Document Type: Article

References (53)

1. Balfour DJK (1989): Influence of nicotine on the release of monoamines in the brain. Prog Brain Res 79:165-172.
2. Bruun RD (1984): Gilles de la Tourette's Syndrome: An overview of clinical experience. J Am Acad Child Adolesc Psychiatry 23: 126-133.
3. Buccafusco JJ, Jackson WJ (1991): Beneficial effects of nicotine administered prior to a delayed matching-to sample task in young and aged monkeys. Neurobiol Aging 12:233-238.
4. Clarke PBS, Hommer DW, Pert A, Skirboll LR (1985): Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol 85:827-835.
5. Cohen DJ, Detlor J, Young JG, Shaywitz BA (1980): Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 37:1350-1357.
6. Comings DE, Comings BG (1988): Tourette's syndrome and attention deficit disorder. In Cohen DJ, Bruun RD, Leckman JF (eds): Tourette's syndrome and tic disorders: Clinical understanding and treatment. Wiley Series in Child and Adolescent Mental Health. New York: John Wiley & Sons, pp 119-135.
7. Connolly J, Boulter J, Heinemann SF (1992): a4-2b/2 and other nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs. Br J Pharmacol 105:657-666.
8. Collins AC, Marks MJ (1996): Are nicotinic receptors activated or inhibited following chronic nicotine treatment? Drug Dev Res 38:231-242.
9. Davidson PW, Kleene BM, Carroll M, Rockowitz RJ (1983): Effects of naloxone on self-injurious behavior: A case study. Appl Res Ment Retardation 4:1-4.
10. Devor EJ, Isenberg KE (1989): Nicotine and Tourette's syndrome. Lancet 8670:1046.
11. Dimitsopuluos T, Kurlan R (1993): Tourette's syndrome and nicotine withdrawal. J Neuropsychiatry 5:108-109.
12. Dursan SM, Reveley MA, Bord R, Stirton F (1994): Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet 344:1577.
13. Emerich DF, Norman AB, Sanberg PR (1991a): Nicotine potentiates the behavioral effects of Haloperidol. Psychopharmacol Bull 27:385-390.
14. Emerich DF, Zanol MD, Norman AB, McConville BJ, Sanberg PR (1991b): Nicotine potentiates haloperidol-induced catalepsy and hyperactivity. Pharmacol Biochem Behav 38:875-880.
15. Erenberg G, Cruse RP, Rothner AD (1987): The natural history of Tourette syndrome: a follow-up study. Ann Neurol 22:383-385.
16. Gonce M, Barbeau A (1977): Seven cases of Gilles de la Tourette's syndrome: Partial relief with clonazepam: A pilot study. Can J Neurol Sci 4:279-283.
17. 3H]dopamine release from mouse striatal synaptosomes. J Neurochem 62:1390-1398.
18. Hakan RL, Ksir CK (1991): Acute tolerance to the locomotor stimulant effects of nicotine in the rat. Psychopharmacology 104: 386-390.
19. Harris D, Silver AA (1995): Tourette's syndrome and learning disorders. Learning Disabil 6:1-7.
20. Henningfield JE, Keenan RM (1993): Nicotine delivery kinetics and abuse liability [Review]. J Consult Clin Psychol 61: 743-750.
21. Hulihan-Giblin BA, Lumpkin MD, Kellar KJ (1989): Effects of chronic administration of nicotine on prolactin release in the rat: Inactivation of prolactin response by repeated injections of nicotine. J Pharm Exp Ther 252:21-25.
22. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ (1989): The Yale global tic severity scale: Initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573.
23. Lena C, Changeux JP (1993): Allosteric modulations of the nicotinic acetylcholine receptor. Trends Neurosci 16:181-186.
24. Levin ED (1992): Nicotinic systems and cognitive function. Psychopharmacology 108:417-431.
25. Levin ED, Briggs SJ, Christopher NC, Rose JE (1992): Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol 58:152-158.
26. Lukas RJ, Ke L, Bencherif M, Eisenhour CM (1996): Regulation by nicotine of its own receptors. Drug Dev Res 38:136-148.
27. McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid MA, Parker KW, Sanberg PR (1991): Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psychiatry 148:793-794.
28. McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, Norman AB (1992): The effects of nicotine plus haloperidol compared to nicotine only and placebo only in reducing tic frequency and severity in Tourette's syndrome. Biol Psychiatry 31:832-840.
29. Montgomery SP, Moss DE, Manderscheid PZ (1985): Tetrahydro-cannabinol and levonatradol effects on extrapyramidal motor behaviors. In Harvey DJ, Paton WDM (eds): Marijuana 84. Oxford: IRL Press, pp 295-302.
30. Moss DE, Manderscherd PZ, Montgomery SP, Norman AB, Sanberg PR (1989): Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome. Life Sci 44: 1421-1525.
31. Ochoa ELM, Chattopadhyay A, McNamee MG (1989): Desensitization of the nicotinic acetylcholine receptor: Molecular mechanisms and effect of modulators. Cell Mol Neurobiol 9:141-178.
32. Ogren SO, Fuxe K (1988): D1- and D2-receptor antagonist induce catalepsy via different efferent. Striatal pathways. Neurosci Lett 85:333-338.
33. Ossowska K, Wedzony K, Wolfarth S (1984): The role of the GABA mechanisms of the globus pallidus in mediating catalepsy, stereotypy and locomotor activity. Pharmacol Biochem Behav 21: 825-831.
34. Pauls DL, Towbin KE, Leckman JF, Zahner GEP, Cohen DJ (1986): Gilles de la Tourette syndrome and obsessive compulsive disorder: Evidence supporting an etiological relationship. Arch Gen Psychiatry 43:1180-1182.
35. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL (1990): Flouxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 29:45-48.
36. Riddle MA, Hardin MT, Ort SI, Leckman JF, Cohen DJ (1988): Behavioral symptoms in Tourette's syndrome. In Cohen DJ, Bruun RD, Leckman JF (eds): Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. Wiley Series in Child and Adolescent Mental Health. New York: John Wiley & Sons, pp 151-162.
37. Robertson MM (1989): The Gilles de la Tourette syndrome: The current status. Br J Psychiatry 154:147-169.
38. Sanberg PR, McConville BJ, Fogelson HM, Manderscheid PZ, Parker KW, Blythe MM, Klykylo WM, Norman AB (1989): Nicotine potentiates the effects of haloperidol in animals and patients with Tourette syndrome. Biomed Pharmacother 43:19-23.
39. Sanberg PR (1980): Haloperidol-induced catalepsy is mediated by post-synaptic dopamine receptors. Nature 284:472-473.
40. Shapiro ES, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordie J, Phillips RA (1989): Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 46:722-730.
41. Shapiro AK, Shapiro ES (1988): Treatment of tic disorders with haloperidol. In Cohen DJ, Bruun RD, Leckman JF (eds): Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. Wiley Series in Child and Adolescent Mental Health. New York: John Wiley & Sons, pp 267-280.
42. Shapiro AK, Shapiro ES, Young JG, Feinberg TE (1988): Gilles de la Tourette Syndrome, Raven Press, New York, pp 417-420.
43. Sharp BM, Beyer S (1986): Rapid desensitization of the acute stimulatory effects of nicotine on rat plasma adrenocorticotropin and prolactin. J Pharm Exp Ther 238:486-491.
44. Silver AA, Hagin RA (1990): Disorders of learning in childhood. Wiley Series in Child and Adolescent Mental Health. New York: John Wiley & Sons, pp 469-508.
45. Silver AA, Shytle RD, Philipp MK, Sanberg PR (1995): Transdermal nicotine in Tourette's syndrome. In Clarke PBS, Quik M, Thurau K (eds): The Effects of Nicotine on Biological Systems. II. Advances in Pharmacological Sciences. Boston: Birkhauser, pp 293-299.
46. Silver AA, Shytle RD, Philipp MK, Sanberg PR (1996): Long term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 35: 1631-1636.
47. Singer HS, Butler IJ, Tune LE, Seifert WE, Coyle JT (1982): Dopaminergic dysfunction in Tourette syndrome. Ann Neurol 12:361-366.
48. Singer HS, Gammon K, Quaskey S (1985-1986): Haloperidol, fluphenazine and clonidine in Tourette syndrome: Controversies in treatment. Pediatr Neurosci 12:71-74.
49. Sivilotti L, Colquhhoun D (1995): Acetylcholine receptors: Too many channels, too few functions. Science 269:1681-1682.
50. Stamenkovic M, Aschauer H, Kasper S (1994): Risperidone for Tourette's syndrome. Lancet 344:1577-1578.
51. Stelf ME, Bornstein RA, Hammond L (1988): A survey of Tourette syndrome patients and their families: The 1987 Ohio Tourette Survey. Ohio Tourette Syndrome Association, Cincinnati.
52. Tourette Syndrome Classification Study Group (1993): Definitions and Classification of Tic Disorders. Arch Neurol 50:1013-1016.
53. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG (1989): Presynaptic modulation of transmitter release by nicotinic receptors. Prog Brain Res 79:157-163.